Home › Companies › ALX Oncology Holdings Inc. › 2025-2026
At ALX Oncology Holdings Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 53 asset managers reported how they voted in their SEC Form N-PX filings, covering 197 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote to approve named executive officer compensation. — ALX Oncology Holdings Inc.'s filing reports the proposal as approved, with 86% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALX Oncology Holdings Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ALX Oncology Holdings Inc.’s Form 8-K, filed June 11, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 10, 2026: 5 items on ALX Oncology Holdings Inc.’s Form 8-K, filed June 11, 2026: 3 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore ALX Oncology Holdings Inc. in the interactive database Compare manager voting policies
These tallies are ALX Oncology Holdings Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Daniel Curran, M.D. | 100,933,233 | -- | -- | 57,798 | 18,313,833 | 99.9% | Elected | — |
| Elect Director: Rekha Hemrajani | 82,732,430 | -- | -- | 18,258,601 | 18,313,833 | 82% | Elected | — |
| Elect Director: Chris Takimoto, M.D., Ph.D., F.A.C.P. | 100,946,696 | -- | -- | 44,335 | 18,313,833 | 99.9% | Elected | — |
| 2. Advisory Vote on the Compensation of the Company's Named Executive Officers | 84,540,061 | 13,497,711 | 2,953,259 | -- | 18,313,833 | 86% | Approved | — |
| 3. Ratification of the Appointment of Independent Registered Public Accounting Firm | 119,293,775 | 1,797 | 9,292 | -- | -- | 99.9% | Approved | — |
Source: ALX Oncology Holdings Inc., Form 8-K, filed with the SEC on June 11, 2026 — read the filing on EDGAR.
Each item below shows how the 53 asset managers that disclosed a ALX Oncology Holdings Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ALX Oncology Holdings Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Daniel Curran, M.D.
ALX Oncology Holdings Inc.’s own tally for this item (“Elect Director: Daniel Curran, M.D.”): 100,933,233 for, 57,798 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class II Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 4,319,298 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,664,664 | 0 | 0 | 0 | For |
| Fidelity | 408,118 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 226,072 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 11,100 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| American Century | 4,191 | 0 | 0 | 0 | For |
| Invesco | 189 | 0 | 0 | 0 | For |
| Guggenheim | 105 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Rekha Hemrajani
ALX Oncology Holdings Inc.’s own tally for this item (“Elect Director: Rekha Hemrajani”): 82,732,430 for, 18,258,601 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class II Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 4,069,669 for, 244,755 withheld, 4,875 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,661,362 | 0 | 16 | 3,287 | For |
| Fidelity | 408,118 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 226,072 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 11,100 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 4,859 | 0 | Abstain |
| American Century | 0 | 0 | 0 | 4,191 | Withhold |
| Invesco | 189 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 0 | 0 | 105 | Withhold |
Combines 2 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Chris Takimoto, M.D., Ph.D., F.A.C.P.
ALX Oncology Holdings Inc.’s own tally for this item (“Elect Director: Chris Takimoto, M.D., Ph.D., F.A.C.P.”): 100,946,696 for, 44,335 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class II Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 4,314,357 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,664,582 | 0 | 0 | 0 | For |
| Fidelity | 408,118 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 226,072 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 11,100 | 0 | 0 | 0 | For |
| American Century | 4,191 | 0 | 0 | 0 | For |
| Invesco | 189 | 0 | 0 | 0 | For |
| Guggenheim | 105 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
100% of fund votes cast · no official result
The 2 asset managers below reported 4,941 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| Vanguard | 82 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
86% Approved · of votes cast
Description as filed by funds: Advisory vote to approve named executive officer compensation.
ALX Oncology Holdings Inc.’s own tally for this item (“2. Advisory Vote on the Compensation of the Company's Named Executive Officers”): 84,540,061 for, 13,497,711 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,663,057 | 1,605 | 3 | 0 | For |
| Fidelity | 408,118 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 226,072 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 11,100 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| American Century | 4,191 | 0 | 0 | 0 | For |
| Invesco | 189 | 0 | 0 | 0 | For |
| Guggenheim | 105 | 0 | 0 | 0 | For |
Fund voting reports, all 8 managers: 4,317,691 for, 1,605 against, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 13,011,849 | 0 | 0 | 0 | For |
| venBio Partners LLC | 12,884,638 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 0 | 7,457,788 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 5,734,620 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 3,184,713 | 0 | 0 | 0 | For |
| Blackstone Inc. | 3,083,569 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 3,057,325 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 3,024,435 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 0 | 2,858,371 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,000,000 | 0 | 0 | 0 | For |
| Two Sigma | 1,552,992 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 950,550 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 819,269 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 488,165 | 0 | 0 | 0 | For |
| BlackRock | 316,274 | 0 | 0 | 0 | For |
| Vanguard | 288,135 | 0 | 0 | 0 | For |
| Goldman Sachs | 238,266 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 226,072 | 0 | 0 | 0 | For |
| Renaissance | 196,680 | 0 | 0 | 0 | For |
| State Street | 186,728 | 0 | 0 | 0 | For |
| Northern Trust | 64,945 | 0 | 0 | 0 | For |
| Point72 | 57,257 | 0 | 0 | 0 | For |
| Graham Capital Management, L.P. | 56,119 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 50,000 | 0 | 0 | 0 | For |
| Callan Family Office, LLC | 22,419 | 0 | 0 | 0 | For |
Institutional-manager reports, all 48 managers: 48,552,292 for, 13,343,744 against, 715 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2026.
ALX Oncology Holdings Inc.’s own tally for this item (“3. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 119,293,775 for, 1,797 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 8 asset managers below reported 4,319,298 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,664,664 | 0 | 0 | 0 | For |
| Fidelity | 408,118 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 226,072 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 11,100 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| American Century | 4,191 | 0 | 0 | 0 | For |
| Invesco | 189 | 0 | 0 | 0 | For |
| Guggenheim | 105 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 134,562,917 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.72% |
| 2 | Fidelity | 0.30% |
| 3 | BRIDGEWAY FUNDS INC | 0.17% |
| 4 | Blackstone Alternative Investment Funds | <0.01% |
| 5 | MASTER INVESTMENT PORTFOLIO | <0.01% |
| 6 | American Century | <0.01% |
| 7 | Invesco | <0.01% |
| 8 | Guggenheim | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 9.67% |
| 2 | venBio Partners LLC | 9.58% |
| 3 | Redmile Group, LLC | 5.54% |
| 4 | DRIEHAUS CAPITAL MANAGEMENT LLC | 4.26% |
| 5 | Vivo Capital, LLC | 2.37% |
| 6 | Blackstone Inc. | 2.29% |
| 7 | 5AM Venture Management, LLC | 2.27% |
| 8 | MARSHALL WACE, LLP | 2.25% |
| 9 | ORBIMED ADVISORS LLC | 2.12% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.49% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 9.75% | 13G |
| Adelman Robert J | 9.65% | 13D |
| GOODMAN COREY S | 9.61% | 13D |
| Redmile Group, LLC | 6.85% | 13G |
| HBM Healthcare Investments (Cayman) Ltd. | 6.38% | 13G |
| Chen Yu | 4.20% | 13G |
| Michael A Carusi | 2.19% | 13D |
| Millennium Management | 1.48% | 13F |
| Vanguard Group | 1.21% | 13F |
| Two Sigma | 1.18% | 13F |
Percentages above are of 134,562,917 shares outstanding, as reported by ALX Oncology Holdings Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALX Oncology Holdings Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ALX Oncology Holdings Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “ALX Oncology Holdings (ALXO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alx-oncology-holdings-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.